| Editura Global Info / Dicţionar englez-român |
MOIETY
| Pronunție (USA): |  | (GB): | |
Traducere în limba română
moiety substantiv
1. jumătate.
2. jumătate parte; parte.
3. (glumeţ) soţie; (rar) soţ.
Exemple de propoziții și/sau fraze:
The PEG moiety lowers the clearance of interferon alpha-2a, thereby extending the duration of its therapeutic effects, but may also reduce interferon-mediated stimulation of an immune response.
(Peginterferon alfa-2a, NCI Thesaurus)
Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability.
(Oraxol, NCI Thesaurus)
The proprietary humanized catalytic IgG1 monoclonal aldolase antibody contains reactive lysine residues in its binding sites, which react covalently with compounds having a diketone function; the Ang2 and VEGFR peptide moieties are then covalently attached to the diketone linkers via a proprietary spacer.
(Ang2/VEGF-Binding Peptides-Antibody Fusion Protein CVX-241, NCI Thesaurus)
Although the exact relationship between DNA binding and its activity has yet to be fully elucidated, amsacrine intercalates DNA through its acridine moiety, and its nonintercalative headgroup impedes topoisomerase II activity, augmenting enzyme-mediated DNA cleavage and resulting in DNA double-strand breaks.
(Amsacrine Lactate, NCI Thesaurus)
Subsequently, the Fas-c (Fas-chimeric) death receptor, containing Fas and tumor necrosis factor (TNF) receptor 1 (TNFR1) moieties, is expressed in angiogenic endothelial cells; endothelial cell-specific Fas-mediated apoptosis is initiated by the binding of TNF-alpha, abundant in the tumor microenvironment, to the TNFR1 moiety of the expressed Fas-c death receptor.
(Angiogenesis Inhibitor GT-111, NCI Thesaurus)
In addition, binding of the IgG1 moiety of this agent to the Fc gamma receptor on the surface of natural killer (NK)cells may bridge NK cells and target T lymphocytes, initiating NK cell-mediated apoptosis of T lymphocytes.
(Alefacept, NCI Thesaurus)
The targeting peptide SF1174 moiety of pan-PI3K/mTOR inhibitor SF1126 selectively binds to cell surface integrins and, upon cell entry, the agent is hydrolyzed to the active drug SF1101; SF1101 selectively inhibits all isoforms of phosphoinositide-3-kinase (PI3K) and other members of the PI3K superfamily, such as the mammalian target of rapamycin (mTOR) and DNA-PK.
(pan-PI3K/mTOR Inhibitor SF1126, NCI Thesaurus)
In addition, after the internalization of this agent and lysosomal degradation, the DM1 moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and eventually causing cell death in CD37-positive B-cells.
(Anti-CD37 Antibody-Drug Conjugate IMGN529, NCI Thesaurus)
The milatuzumab moiety of this ADC selectively binds to CD74 on tumor cell surfaces; upon internalization, the doxorubicin moiety is released, where it intercalates between base pairs in the DNA helix and inhibits topoisomerase II, thereby preventing DNA replication and increasing double-strand breakage.
(Milatuzumab-Doxorubicin Antibody-Drug Conjugate, NCI Thesaurus)
Upon administration of a biotin-based radioconjugate, the biotin moiety of the radioconjugate binds to the streptavidin moiety of anti-CD45 BC8 antibody-streptavidin conjugate and, upon cellular internalization, specifically delivers cytotoxic radiation to CD45-expressing tumor cells.
(Anti-CD45 BC8 Monoclonal Antibody-Streptavidin Conjugate, NCI Thesaurus)
TE-AR MAI PUTEA INTERESA
